Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 180

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 180
---
) 690,000 shares of Common Stock issuable upon exercise of vested stock options and options exercisable within 
 60 days from the date of this Prospectus                                                                                            |

| (4) | Includes 5,840,000 common                                                                      
 stock. David Safren has the sole voting and investment power over the shares held by SBDHEI LP |

| (5) | Includes (i) 5,785,410                                                                                                               
 common stock, and (ii) 1,171,875 shares of Common Stock issuable upon exercise of warrants, exercisable within 60 days from the date 
 of this Prospectus. Yitzchak Rokovsky has the sole voting and investment power over the shares held by Third Eye Investors LLC.      |

| (6) | Includes (i) 3,969,890                                                                                                            
 common stock, and (ii) 781,250 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days from the date 
 of this Prospectus.                                                                                                               |

| (7) | Includes (i) 2,375,000                                                                                                              
 common stock, and (ii) 1,187,500 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days from the date 
 of this Prospectus.                                                                                                                 |

<div align='center'>112

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</div>

Related Party Transactions

The following is a description of transactions since January 1, 2023, to which we were a party or will be a party, in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last three completed fiscal years, and in which any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest.

On December 31, 2024, the Company’s Chief
Operating Officer, exercised 2,800,000 stock options into 2,800,000 common stock at an exercise price of $0.001 per share.

On December 31, 2024, the Company’s Board
of Directors approved a grant to the Chief Technology Officer of LipoVation, the Company’s subsidiary, 740,000 stock options at
an exercise price of